Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MECP2 | P51608 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27088365 | 1.00 | TEK (0.45) | TEKKDRCYP19A1LRRK2EPHB4 | |
| SCHEMBL19697583 | 0.83 | CA2 (0.48) | TEKKDRCYP19A1EPHB4TSHR | |
| SCHEMBL22050888 | 0.81 | CHRNB2 (0.46) | CYP19A1LRRK2KDM4EMEN1MAPT | |
| SCHEMBL21286181 | 0.81 | KDR (0.45) | TEKKDRCYP19A1EPHB4TSHR | |
| SCHEMBL25820297 | 0.81 | CYP19A1 (0.51) | CYP19A1LRRK2 | |
| SCHEMBL19449446 | 0.80 | CHRNB2 (0.51) | NPC1RAB9AALDH1A1KDM4EMEN1 | |
| SCHEMBL9963176 | 0.80 | CYP19A1 (0.66) | KDRCYP19A1EPHB4TSHRNPC1 | |
| SCHEMBL29979963 | 0.79 | TEK (0.48) | TEKKDREPHB4TSHRRECQL | |
| SCHEMBL13886476 | 0.79 | TEK (0.48) | TEKKDREPHB4TSHRRECQL | |
| SCHEMBL23026391 | 0.78 | CYP19A1 (0.52) | KDRCYP19A1EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2024-10-03 | — | — | US | disclosed |
| EP-4320109-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | Tolremo Therapeutics AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| CN-117355512-A | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | 托雷莫治疗股份公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022214606-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | TEK 3011/4885KDR 4443/4885CYP19A1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.